Medtronic launches study of drug-eluting stent as treatment for bifurcation lesions

Medtronic (NYSE:MDT) today launched a study to evaluate the safety and efficacy of its Resolute Onyx drug-eluting stent for the treatment of bifurcation lesions in patients with coronary artery disease. The medtech giant said that bifurcation lesions make up nearly 20% of all percutaneous coronary interventions. The assessment of DES tech in this patient group is part of Medtronic’s post-approval study of its Resolute Onyx device. Get the full story at our sister site, Drug Delivery Business News. The post Medtronic launches study of drug-eluting stent as treatment for bifurcation lesions appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Medtronic Source Type: news